CDSCO panel grants clearance to Morepen Labs to conduct BE studies for fatty liver disease drug Resmetirom Ruchika Sharma29 April 2025 4:11 PM ISTGurugram: Morepen Laboratories Ltd. has received clearance from the Subject Expert Committee (SEC) of Central Drugs Standard Control...
FDA Approves First Treatment for Patients with Liver scarring Due to NASH Dr. Kamal Kant Kohli15 March 2024 10:30 PM ISTThe U.S. Food and Drug Administration has approved Rezdiffra (resmetirom) for treatment of adults with noncirrhotic non-alcoholic steatohepatitis...
Obeticholic Acid may Improve outcomes in NASH-Related Liver Fibrosis Jacinthlyn Sylvia7 Jan 2024 9:15 PM ISTA new study published in Journal of Hepatology confirms the efficacy of Obeticholic Acid (OCA), a novel farnesoid X receptor agonist and antifibrotic...
Bariatric metabolic surgery effective in treating non-alcoholic steatohepatitis: Lancet Jacinthlyn Sylvia6 May 2023 10:30 AM ISTWhen treating non-alcoholic steatohepatitis (NASH), bariatric-metabolic surgery is more successful than lifestyle modifications and improved medical...
Resmetirom lowers markers of CV risk and fibrosis among patients with NASH cirrhosis Jacinthlyn Sylvia29 Dec 2022 8:00 PM ISTIn patients with NASH cirrhosis treated with resmetirom for up to 52 weeks, cardiovascular (CV) risk and non-alcoholic steatohepatitis (NASH) fibrosis...
Pegozafermin effectively lowers liver fat and blood lipid levels in NASH patients: Lancet Jacinthlyn Sylvia22 Dec 2022 8:00 PM ISTA new study conducted by Rohit Loomba and team showed that Pegozafermin was usually well tolerated and linked to clinically significant decreases in...
Pfizer gets USFDA Fast Track Designation for Ervogastat plus Clesacostat to treat NASH Ruchika Sharma28 May 2022 11:57 AM ISTDiacylglycerol O-acyltransferase 2 (DGAT2) and acetyl-CoA carboxylase (ACC) are two key enzymes that regulate lipid metabolism. Inhibitors of ACC and...
Zydus randomises 'first patient' in phase 2 trial of Saroglitazar Mg in NASH Ruchika Sharma23 Oct 2021 12:47 PM ISTAhmedabad: Zydus, a global pharmaceutical company has recently announced that the company has randomised the first patient into the Phase 2(b)...
NASH and NAFLD: Case Based Discussion. Dr Dinesh Jothimani6 Oct 2021 4:29 PM ISTCase Based Discussion on Non-alcoholic steatohepatitis (NASH) and Non-alcoholic fatty liver disease (NAFLD)
Experimental drug shows promise in treatment of NAFLD in phase 2 trial Hina Zahid14 Aug 2021 9:00 AM ISTUSA: An experimental, oral, once-daily, selective fatty acid synthase (FASN) inhibitor has shown promise for the treatment of non-alcoholic...
Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease (NAFLD)-Clinical Implications Hina Zahid22 May 2021 9:15 AM ISTIntroduction: Obstructive sleep apnea (OSA) syndrome is a common sleep disorder and is characterized by episodes of complete or partial airway...
